Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells

Lianne E. RotinPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; ;Institute of Medical Science, University of Toronto, Toronto, ON, Canada;

Marcela GrondaPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada;

Rose HurrenPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada;

XiaoMing WangPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada;

Mark D. MindenPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada;

Malik SlassiFluorinov Pharma Inc., Toronto, ON, Canada

Aaron D. SchimmerPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; ;Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Correspondence[email protected]

show all

Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Figure S1: Combination ibrutinib-cytarabine treatment of TEX and OCI-AML2 cells.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Figure S1: Combination ibrutinib-cytarabine treatment of TEX and OCI-AML2 cells.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date